Supriya Lifescience Limited (SUPRIYA.NS)

Supriya Lifescience Limited (SUPRIYA.NS) — VMCI valuation read

SUPRIYA.NS screens at VMCI 55/100, a 5-point gap above the Healthcare sector median (50). For a mid-cap Supriya Lifescience Limited share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

SUPRIYA.NS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: SUPRIYA.NS trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -1.6x leaves covenant headroom, which sets the rate-cycle exposure for Supriya Lifescience Limited.

SUPRIYA.NS rose 0.6% over the trailing 7 days, with a +4.7% read on a 30-day basis.